Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 3 de 3 
Presentar resultados
Seleccionar todas
1.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
2.Tiene citas relacionadas Cita con resumen
Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA, for the Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-38. [Ref.ID 69075]
3.
Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA, for the Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. A randomized trial. JAMA 2002;288:207-15. [Ref.ID 62738]
Seleccionar todas
 
 1 a 3 de 3